Adam I, Elwasila E, Homeida M
New Halfa Teaching Hospital, P.O. Box 61, New Halfa, Sudan.
Ann Trop Med Parasitol. 2005 Jan;99(1):37-40. doi: 10.1179/136485905X17407.
In a prospective study carried out in New Halfa Teaching Hospital, in eastern Sudan, between June 2001 and April 2003, 25 pregnant Sudanese women with schistosomiasis mansoni were each treated with a single oral dose of praziquantel (PZQ), at 40 mg/kg. The drug was given to six (24%), 12 (48%) and seven (28%) of the women during the first, second and third trimesters of their pregnancies, respectively. The patients were followed-up until delivery and their babies were followed-up until they were 1 year old. Although one patient, who received PZQ after 10 weeks of gestation, aborted (3 weeks post-treatment), this frequency of abortion is similar to that seen in the local community. None of the treated women died, and there were no stillbirths or congenital abnormalities in the newborn babies. Although this is a small trial, it appears that PZQ is a safe drug to use against schistosomiasis mansoni, even during the first trimester of pregnancy.
2001年6月至2003年4月期间，在苏丹东部的新哈尔法教学医院进行了一项前瞻性研究。25名患有曼氏血吸虫病的苏丹孕妇每人接受了一次口服吡喹酮（PZQ）治疗，剂量为40mg/kg。分别在妊娠的第一、第二和第三个月，有6名（24%）、12名（48%）和7名（28%）妇女接受了该药物治疗。对患者进行随访直至分娩，并对其婴儿进行随访直至1岁。尽管有一名在妊娠10周后接受PZQ治疗的患者流产（治疗后3周），但这种流产发生率与当地社区的情况相似。接受治疗的妇女均未死亡，新生儿中也没有死产或先天性异常。尽管这是一项小型试验，但似乎吡喹酮是一种治疗曼氏血吸虫病的安全药物，即使在妊娠的第一个月也是如此。
